Actinic keratosis treatment recalled due to growing skin cancer concerns

Healthcare professionals have been advised to stop prescribing ingenol mebutate (Picato) and consider other treatment options following a product recall by LEO Laboratories.

by Sandhiya Sodha
Post-marketing reports of various types of skin cancer in patients using ingenol mebutate gel have been received by the MHRA. | DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Post-marketing reports of various types of skin cancer in patients using ingenol mebutate gel have been received by the MHRA. | DR P. MARAZZI/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package